Approaches to Oligometastatic Renal Cell Carcinoma

Purpose of ReviewThis study aims to gather the current state of the literature about therapeutic approaches and management of oligometastatic renal cell carcinoma.Recent FindingsTwo recent stereotactic body radiotherapy (SBRT) studies gained attention and offered a promising outcome alone or in association with antineoplastic drugs especially in oligometastatic renal cell carcinoma.If one can consider evidence-based medicine as the sole therapeutic option, many unresolved questions are still pending. Thus, therapeutic approaches in oligometastatic renal cell carcinoma are still working. Further phase III clinical trials are urgently needed to validate the last 2 phase II involving SBRT and improve knowledge for defining the right care to the right patient at the right time. In addition, a discussion in a disciplinary consultation meeting remains essential to validate the arrangement between systemic treatments and focal treatments that will best benefit the patient.

Automated summary

This study aims to gather the current literature on therapeutic approaches and management of oligometastatic renal cell carcinoma. Two recent stereotactic body radiotherapy (SBRT) studies have shown promising outcomes, either alone or in combination with antineoplastic drugs, for oligometastatic renal cell carcinoma. However, many unresolved questions remain, and further phase III clinical trials are urgently needed to validate the findings and improve patient care. Additionally, interdisciplinary discussions are essential to determine the best arrangement between systemic and focal treatments for optimal patient benefit.